title: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome.
abstract: BACKGROUND
  Post-infectious irritable bowel syndrome is associated with increased serotonin-containing enterochromaffin cells and lymphocytes in rectal biopsies. Animal studies have suggested that steroids reduce the lymphocyte response and suppress some of the post-infectious changes in neuromuscular function.
  
  
  OBJECTIVE
  To evaluate whether steroids reduce the number of enterochromaffin cells and improve the symptoms of post-infectious irritable bowel syndrome.
  
  
  METHODS
  Twenty-nine patients with post-infectious irritable bowel syndrome underwent a randomized, double-blind, placebo-controlled trial of 3 weeks of oral prednisolone, 30 mg/day. Mucosal enterochromaffin cells, T lymphocytes and mast cells were assessed in rectal biopsies before and after treatment, and bowel symptoms were recorded in a daily diary.
  
  
  RESULTS
  Initial enterochromaffin cell counts were increased and correlated with initial lamina propria T-lymphocyte counts (r = 0.460, P = 0.014). Enterochromaffin cell counts did not change significantly after either prednisolone (- 0.8% +/- 9.2%) or placebo (7.9% +/- 7.9%) (P = 0.5). Although lamina propria T-lymphocyte counts decreased significantly after prednisolone (22.0% +/- 5.6%, P = 0.003), but not after placebo (11.5% +/- 8.6%, P = 0.1), this was not associated with any significant treatment-related improvement in abdominal pain, diarrhoea, frequency or urgency.
  
  
  CONCLUSIONS
  Prednisolone does not appear to reduce the number of enterochromaffin cells or cause an improvement in symptoms in post-infectious irritable bowel syndrome. Other approaches to this persistent condition are indicated.
authors.affiliation: Division of Gastroenterology, University Hospital, Nottingham, UK.
authors.forename: S P
authors.initials: SP
authors.lastname: Dunlop
authors.forename: D
authors.initials: D
authors.lastname: Jenkins
authors.forename: K R
authors.initials: KR
authors.lastname: Neal
authors.forename: J
authors.initials: J
authors.lastname: Naesdal
authors.forename: M
authors.initials: M
authors.lastname: Borgaonker
authors.forename: S M
authors.initials: SM
authors.lastname: Collins
authors.forename: R C
authors.initials: RC
authors.lastname: Spiller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001706:Biopsy / Q000379:methods; D002452:Cell Count; D003109:Colonic Diseases, Functional / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D011239:Prednisolone